ML327

€1,131.00

Excl. VAT

Item no.	HY-103038-100mg
Manufacturer	MedChem Express
CASRN	1883510-31-3
Amount	100 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer Colorectal Cancer Nervous System Cancer
Type	Inhibitors
Specific against	other
Purity	98.06
Formula	C19H18N4O4
Citations	[1]Rellinger EJ, et al. Isoxazole compound ML327 blocks MYC expression and tumor formation in neuroblastoma. Oncotarget. 2017 Jul 20;8(53):91040-91051. [2]An H, et al. Small molecule/ML327 mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition.Oncotarget. 2015 Sep 8;6(26):22934-48.
Smiles	O=C(C1=CC=CNC1=O)NCCCNC(C2=NOC(C3=CC=CC=C3)=C2)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1883510-31-3
Available
Product Description	ML327 is a blocker of MYC which can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-programmed cell death
Molecular Weight	366.37
Clinical Information	No Development Reported
Solubility	DMSO : 32 mg/mL (ultrasonic; warming)
Pathway	Apoptosis; Autophagy
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-103038-100mg-safety-datasheet.pdf